Eczema Therapeutics Market, by Treatment (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics, Immunomodulators, and Interleukin inhibitors), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and O

Eczema Therapeutics Market, by Treatment (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics, Immunomodulators, and Interleukin inhibitors), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Eczema, or dermatitis or atopic dermatitis, is a skin disease that results in inflammation of the skin. A person suffering from eczema suffers from rashes, redness of skin, and itchiness. This skin condition is most common in children and is also seen in the adult population. The symptoms of eczema are different from person to person. Dry itchy red skin, skin rashes, bumpy rashes, and blisters are some of the most common symptoms of this skin disease. Diagnosis of eczema is mostly based on physical examination and in few cases, skin biopsy is performed. The eczema therapeutics aims to control symptoms by reducing inflammation and relieve skin itchiness.

Market Dynamics
Market players are indulged in research and development activities for the treatment of eczema or atopic dermatitis, this is expected to increase the growth of the global eczema therapeutics market over the forecast period. For instance, the researchers at the Oregon Health & Science University, published their research in the New England Journal of Medicine online edition as well as presented their findings at a presentation at the European Academy of Dermatology and Venereology. Their research shows that drug Dupilumab, indicated for atopic dermatitis or eczema, alleviated the skin lesions and intense itching that were previously untreatable by standard medications and often impacted large areas of a trial participant’s body. In turn, the drug also reduced sleep deprivation, depression, and anxiety in participants who suffered from these symptoms because of the severity of eczema.

Increasing awareness for the treatment as well as management of eczema is expected to increase the growth of the global eczema therapeutics market over the forecast period. There are many organizations that are dealing with eczema. They are National Eczema Foundation, National Eczema Society, National Organization of Rare Diseases, International Eczema Council, and Eczema Foundation. Moreover, the Eczema Foundation is under partnership with other institutions and organizations, in order to increase knowledge as well as availability of the treatment options for the eczema, such as Association of the people affected with Atopic Dermatitis, Imperial College London, Eczema Outreach Support, French Association for the prevention of Allergies, and International Society of Atopic Dermatitis etc.

Key features of the study:
This report provides an in-depth analysis of global eczema therapeutics market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global eczema therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Sanofi S.A., Encore Dermatology Inc., AbbieVie Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Anacor Pharmaceuticals Inc., Meda AB, GlaxoSmithKline plc, AstraZeneca plc, and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global eczema therapeutics market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the eczema therapeutics market
Detailed Segmentation:
Global Eczema Therapeutics Market, By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
Global Eczema Therapeutics Market, By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
Global Eczema Therapeutics Market, By Region:
North America
By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment:
Corticosteroids
Emollients/Moisturizers
Antihistamines
Calcineurin inhibitors
Antibiotics
Immunomodulators
Interleukin inhibitors
By Distribution Channel:
Hospitals and Clinics
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Sanofi S.A.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Encore Dermatology Inc.
AbbieVie Inc.
F. Hoffmann-La Roche AG
Novartis AG
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
Anacor Pharmaceuticals Inc.
Meda AB
GlaxoSmithKline plc
AstraZeneca plc.
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.